Explo Solution Spółka z Ograniczoną Odpowiedzialnością (KRS 0000583923, NIP 5252634876) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. EXPLO SOLUTION operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since November 3, 2015. EXPLO SOLUTION's most recently reported net revenue was 154.8 K PLN for 2024.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Explo Solution
Identity
- Name
- Explo Solution Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- November 3, 2015
- Registry status as of
- November 21, 2025
- Latest entry
- October 30, 2025
- Founding act
- 12.10.2015 R., MAGDALENA WITKOWSKA, KANCELARIA NOTARIALNA W WARSZAWIE; REP. A NR 7469/2015
Articles of association history (3)
- October 12, 2015: 12.10.2015 R., MAGDALENA WITKOWSKA, KANCELARIA NOTARIALNA W WARSZAWIE; REP. A NR 7469/2015
- February 28, 2023: 28.02.2023 R., REP. A 1044/2023, NOTARIUSZ MAGDALENA WITKOWSKA, KANCELARIA NOTARIALNA W WARSZAWIE, UL. SZARA 14 LOK. 15, DODANO PKT. 67, 68, 69 W § 3 UST. 1 UMOWY SPÓŁKI ORAZ PRZYJĘTO TEKST JEDNOLITY UMOWY SPÓŁKI
- December 27, 2023: 27.12.2023 R., REP. A NR 7714/2023, NOTARIUSZ MAGDALENA WITKOWSKA, KANCELARIA NOTARIALNA W WARSZAWIE, UL. SZARA 14 LOK. 15; ZMIENIONO § 5 UST. 1 ORAZ § 5 UST. 4 UMOWY SPÓŁKI ORAZ PRZYJĘTO TEKST JEDNOLITY UMOWY SPÓŁKI.
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Address and contact
- Address
- UL. CZERWONEGO KRZYŻA, 2, 5, 00-377, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.2298, 21.0117approx.
Risk and payment profile - Explo Solution
Credibility rating
22.5 / 100
Poor credibility
Insolvency risk
High
Significant formal threat
Closure risk
31
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
Spółka wykazuje sygnały niestabilności organizacyjnej: częste zmiany właścicieli. Może to wskazywać na podwyższone ryzyko współpracy.
Shareholder changes
8
8/10 yrs
Board changes
1
1/10 yrs
PKD changes
0
0/10 yrs
Name changes
0
0/10 yrs
Data from 10 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: E (23/100)
Trend: deteriorating (-35.8 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2018–2024
Current: 1.4 K PLN
Safe: 199.72 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Explo Solution
Founded
November 3, 2015
10 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
100.0 K PLN
50 shares total
Shareholders
2
shareholders
Board
1 person
Filed years
7 years
2018–2024 · profitable: 3/7
Registry entries
38
latest: October 30, 2025
Risk signals
Revenue
154.8 K PLN
2024
Net profit
-25.0 K PLN
2024
Assets
135.8 K PLN
2024
Equity
83.0 K PLN
2024
EBITDA
-6.4 K PLN
2024
Valuation
23.0 K PLN
Low confidence
Low confidence
Companies in the same location
EU Funds
Projects co-financed by the European Union for Explo Solution - total value, EU contribution and the company's largest awards.
Projects
1
EU co-financing
51.0 K PLN
Total project value
73.7 K PLN
Eligible spending
60.0 K PLN
Funds
Operational programmes
- Program Operacyjny Inteligentny Rozwój
Largest projects
Top 1 by EU co-financing
| Project | Fund | EU co-financing | Value | Rate | Period |
|---|---|---|---|---|---|
Zaawansowana technologia pirolizy i oczyszczania produktów |
Public procurement
Trademarks
Reviews
Rate business credibility - Explo Solution.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
